- July 01, 2022
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical to Provide Matching Funds to Select Crowdfunded Projects Addressing Issues in the Field of Oncology the Second "Taiho Smile Support"
Taiho Pharmaceutical Co., Ltd. announced today the launch of the second Taiho Smile Support, the company’s unique social contribution program. Under the program, Taiho Pharmaceutical will solicit project proposals on the theme of “Challenging Issues in the Field of Oncology” via its website from July 1 to September 30, 2022.
Taiho Smile Support is a social contribution program that supports organizations and individuals seeking to work on solving various social issues in the field of oncology that cannot be solved by drugs alone, using crowdfunding. If a selected organization or individual starts crowdfunding and is able to raise 50% of the amount needed to carry out the project, they will also receive a matching funds from Taiho Pharmaceutical equal to 50% of the amount needed to carry out the project.
In the first Taiho Smile Support, Taiho Pharmaceutical donated a total of 4.17 million yen in matching funds to three projects. Those three projects are currently underway.
(Taiho Smile Support: — available only in Japanese)
Through this program, Taiho Pharmaceutical aims to support the dreams of organizations and individuals who are working to address challenges in the field of oncology. In partnership with these organizations, individuals, and all of the people who support them via crowdfunding, Taiho Pharmaceutical seeks to create a world where the precious moments of everyday life keep flowing for people with cancer and their families.
Second Taiho Smile Support
Application period |
July 1 to September 30, 2022 |
Result announcement |
Late November 2022 |
Crowdfunding implementation period |
November 2022 to April 30, 2023 |
Matching funds disbursement |
Early June 2023 |
Project implementation period |
June 2023 to May 2024 |
Project implementation report |
Please submit a report to Taiho Pharmaceutical within three months after the project implementation is completed. |
Information in this news release was current as of the original release date.
Taiho Pharmaceutical's press releases may contain information about prescription drugs including products currently under development, however information contained in the press releases are not intended to constitute promotion, advertisement, or medical advice.